{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:13:04Z","timestamp":1784106784796,"version":"3.55.0"},"reference-count":44,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Janus kinase (JAK)\/tyrosine kinase 2 (TYK2) inhibitors are novel treatments for moderate-to-severe plaque psoriasis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>To perform a network meta-analysis to compare the efficacy and safety of TYK2 inhibitors with other oral drugs in moderate-to-severe psoriasis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Eligible randomised clinical trials (RCTs) were identified from public databases (published before November 2, 2023). Random-effect frequentist network meta-analysis was performed with ranking based on the surface under the cumulative ranking curve (SUCRA) of Physician\u2019s Global Assessment of \u201cclear\u201d or \u201calmost clear\u201d (PGA 0\/1), 75% reduction from baseline in Psoriasis Area and Severity Index (PASI-75).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Twenty RCTs containing 7,564 patients with moderate-to-severe psoriasis were included. Deucravacitinib at all dose levels (except for 3 mg every other day) and tofacitinib (10 mg BID) ranked best in achieving PGA 0\/1 and PASI-75 at 12\u2013 16 weeks. Tofacitinib (10 mg BID) was considered the most unsafe. Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment.<\/jats:p>\n<jats:p>Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Limitation<\/jats:title>\n<jats:p>Insufficiency of eligible data and no long-term follow-up data.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Deucravacitinib showed superior efficacy and safety for treating moderate-to-severe psoriasis over other included drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_775_2023","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T10:22:06Z","timestamp":1717410126000},"page":"590-598","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative efficacy and safety of JAK\/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis"],"prefix":"10.25259","volume":"90","author":[{"given":"Yaxuan","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichun","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"10.25259\/IJDVL_775_2023\/ref-1","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.25259\/IJDVL_775_2023\/ref-2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.25259\/IJDVL_775_2023\/ref-3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.25259\/IJDVL_775_2023\/ref-4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-5","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1111\/ced.15377","article-title":"Evolving utility of apremilast in dermatological disorders for off-label indications","volume":"47","author":"Mehta","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.tips.2021.01.004","article-title":"Emerging therapeutic applications for fumarates","volume":"42","author":"Hoogendoorn","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.25259\/IJDVL_775_2023\/ref-8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.25259\/IJDVL_775_2023\/ref-9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/13543776.2019.1567713","article-title":"Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015\u20132018)","volume":"29","author":"He","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.25259\/IJDVL_775_2023\/ref-10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase\u2012signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.25259\/IJDVL_775_2023\/ref-12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/intimm\/dxt062","article-title":"Tyk2 is a therapeutic target for psoriasis-like skin inflammation","volume":"26","author":"Ishizaki","year":"2014","journal-title":"Int Immunol"},{"key":"10.25259\/IJDVL_775_2023\/ref-13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"10.25259\/IJDVL_775_2023\/ref-14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.25259\/IJDVL_775_2023\/ref-15","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1177\/12034754221141680","article-title":"Clinical implications of targeting the JAK-STAT pathway in psoriatic disease: emphasis on the TYK2 pathway","volume":"27","author":"Loo","year":"2023","journal-title":"J Cutan Med Surg"},{"key":"10.25259\/IJDVL_775_2023\/ref-16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.25259\/IJDVL_775_2023\/ref-17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.25259\/IJDVL_775_2023\/ref-18","first-page":"470","article-title":"Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased","volume":"316","author":"Irwig","year":"1998","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.25259\/IJDVL_775_2023\/ref-19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.25259\/IJDVL_775_2023\/ref-21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO- 1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-23","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: Phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.25259\/IJDVL_775_2023\/ref-26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.25259\/IJDVL_775_2023\/ref-27","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jaad.2016.07.040","article-title":"Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis","volume":"75","author":"Feldman","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-31","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_775_2023\/ref-32","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_775_2023\/ref-33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-35","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.25259\/IJDVL_775_2023\/ref-36","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_775_2023\/ref-37","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-38","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1365-2133.2010.10195.x","article-title":"Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: A multicentre prospective randomized controlled clinical trial","volume":"164","author":"Fallah Arani","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-39","doi-asserted-by":"publisher","first-page":"1180170","DOI":"10.3389\/fimmu.2023.1180170","article-title":"Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: A network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_775_2023\/ref-40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO- 1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-43","doi-asserted-by":"publisher","first-page":"2154122","DOI":"10.1080\/09546634.2022.2154122","article-title":"Deucravacitinib in the treatment of psoriasis","volume":"34","author":"Estevinho","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_775_2023\/ref-44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.tips.2023.01.004","article-title":"Deucravacitinib (Sotyktu\u2122) for plaque psoriasis","volume":"44","author":"Granau","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.25259\/IJDVL_775_2023\/ref-45","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.25259\/IJDVL_775_2023\/ref-46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.25259\/IJDVL_775_2023\/ref-47","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_775_2023\/ref-48","volume-title":"Deucravacitinib (Sotyktu): CADTH Reimbursement recommendation","year":"2023"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/comparative-efficacy-and-safety-of-jak-tyk2-inhibitors-and-other-oral-drugs-for-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-network-meta-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/comparative-efficacy-and-safety-of-jak-tyk2-inhibitors-and-other-oral-drugs-for-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-network-meta-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:20:44Z","timestamp":1724412044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/comparative-efficacy-and-safety-of-jak-tyk2-inhibitors-and-other-oral-drugs-for-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-network-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":44,"alternative-id":["10.25259\/IJDVL_775_2023"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_775_2023","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"article-number":"590"}}